External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00637637|
Recruitment Status : Unknown
Verified December 2008 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : March 18, 2008
Last Update Posted : August 12, 2013
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether external-beam radiation therapy is more effective with or without indinavir and ritonavir in treating patients with brain metastases.
PURPOSE: This randomized phase II trial is studying external-beam radiation therapy alone to see how well it works compared to external-beam radiation therapy given together with indinavir and ritonavir in treating patients with brain metastases.
|Condition or disease||Intervention/treatment||Phase|
|Cancer||Drug: indinavir sulfate Drug: ritonavir Radiation: radiation therapy||Phase 2|
- Compare the efficacy, in terms of time to treatment failure at CNS level and 4-months treatment failure rate, in patients with brain metastases treated with external-beam radiotherapy in combination with indinavir sulfate and ritonavir versus external-beam radiotherapy alone.
- Prospectively investigate the efficacy of a potentially antiangiogenic agent, indinavir sulfate.
- Investigate the antineoplastic activity of indinavir sulfate in combination with ionizing radiation in cancer patients with metastatic disease to the brain.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo radiotherapy to the brain once daily, 5 days a week for 2 weeks (10 doses total). Patients also receive oral indinavir sulfate and oral ritonavir twice daily for 35 days beginning at day 1 of radiotherapy.
- Arm II: Patients undergo radiotherapy to the brain once daily, 5 days a week for 2 weeks (10 doses total).
Patients complete quality of life questionnaires, including QOL-30 and the Mini Mental Status Examination, at baseline, 2 weeks after completion of radiotherapy, and at 1 and 3 months after completion of study treatment.
After completion of study treatment, patients are followed periodically for at least 4 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Official Title:||Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study|
|Study Start Date :||September 2007|
|Estimated Primary Completion Date :||June 2009|
- Time to treatment failure in the brain (TTF) as determined by the radiological response rate
- Overall survival (OS)
- Radiological volumetric response to treatment
- Local intracranial disease progression at 4 months
- Progression-free survival at 6 months
- Improvement of symptoms
- Time to symptom relapse or symptom progression
- Duration of use of steroids
- Duration of use of anticonvulsive drugs
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00637637
|Hopital Cantonal Universitaire de Geneve||Recruiting|
|Geneva, Switzerland, CH-1211|
|Contact: Contact Person 41-22-372-3270|
|Oncology Institute of Southern Switzerland - Lugano||Recruiting|
|Lugano, Switzerland, CH-6900|
|Contact: Contact Person 41-91-811-9157|
|Zurich, Switzerland, CH-8091|
|Contact: Contact Person 41-107-2004|
|Principal Investigator:||Ilja Ciernik, MD||Oncology Institute of Southern Switzerland|